Advances in Immunotherapy of Multiple Myeloma: From the Discovery of Tumor-Associated Antigens to Clinical Trials |
| |
| Authors: | Maurizio Chiriva-Internati Everardo Cobos W. Martin Kast |
| |
| Affiliation: | 1. Department of Microbiology &2. Immunology and Division of Hematology/Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, Texas, USAmaurizio.chiriva@ttuhsc.edu;4. Immunology and Division of Hematology/Oncology, Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center, Lubbock, Texas, USA;5. Department of Molecular Microbiology &6. Immunology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, California, USA |
| |
| Abstract: | Tumors aberrantly express tumor-associated antigens that can be specifically recognized by T-cells, thereby providing a scientific rationale for the design and clinical testing of immunotherapeutic strategies targeting these antigens. Multiple myeloma is a fatal hematologic malignancy. Here, we review techniques to discover new tumor-associated antigens in multiple myeloma and the latest immunotherapeutic strategies employed in this disease. |
| |
| Keywords: | cancer-testis antigens hematological malignancies immunotherapy |
|
|
